A subtype of cancer-associated fibroblast expressing syndecan-2 (SDC2) predicts survival and immune checkpoint inhibitor response in gastric cancer

Ji-Yong Sung; Jae-Ho Cheong; Kihye Shin; Eui Tae Kim

doi:10.1002/ctm2.70079

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (12) : e70079 DOI: 10.1002/ctm2.70079

LETTER TO THE JOURNAL

A subtype of cancer-associated fibroblast expressing syndecan-2 (SDC2) predicts survival and immune checkpoint inhibitor response in gastric cancer

Ji-Yong Sung ¹^,^†
, Jae-Ho Cheong ²^,^†
, Kihye Shin ³^,⁴
, Eui Tae Kim ³^,⁴^,^†

Author information +

History +

PDF

Cite this article

Download citation ▾

Ji-Yong Sung, Jae-Ho Cheong, Kihye Shin, Eui Tae Kim. A subtype of cancer-associated fibroblast expressing syndecan-2 (SDC2) predicts survival and immune checkpoint inhibitor response in gastric cancer. Clinical and Translational Medicine, 2024, 14(12): e70079 DOI:10.1002/ctm2.70079

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.